Yu J - Search Results

1

Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer.

Murmann AE, Yu J, Opal P, Peter ME. Murmann AE, et al. Among authors: yu j. Trends Cancer. 2018 Oct;4(10):684-700. doi: 10.1016/j.trecan.2018.08.004. Epub 2018 Sep 26. Trends Cancer. 2018. PMID: 30292352 Free PMC article. Review.

2

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, Chen Z, Chen W, Liu X, Salomon AR, Liu H, Weichselbaum RR, Yu J, Peter ME. Qadir AS, et al. Among authors: yu j. Cell Rep. 2017 Mar 7;18(10):2373-2386. doi: 10.1016/j.celrep.2017.02.037. Cell Rep. 2017. PMID: 28273453 Free PMC article.

3

Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.

Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Jin HJ, et al. Among authors: yu j. Cancer Res. 2013 Jun 15;73(12):3725-36. doi: 10.1158/0008-5472.CAN-12-3468. Epub 2013 Mar 28. Cancer Res. 2013. PMID: 23539448 Free PMC article.

4

ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.

Wu L, Zhao JC, Kim J, Jin HJ, Wang CY, Yu J. Wu L, et al. Among authors: yu j. Cancer Res. 2013 Oct 1;73(19):6068-79. doi: 10.1158/0008-5472.CAN-13-0882. Epub 2013 Aug 1. Cancer Res. 2013. PMID: 23913826 Free PMC article.

5

PADI2-Mediated Citrullination Promotes Prostate Cancer Progression.

Wang L, Song G, Zhang X, Feng T, Pan J, Chen W, Yang M, Bai X, Pang Y, Yu J, Han J, Han B. Wang L, et al. Among authors: yu j. Cancer Res. 2017 Nov 1;77(21):5755-5768. doi: 10.1158/0008-5472.CAN-17-0150. Epub 2017 Aug 17. Cancer Res. 2017. PMID: 28819028

6

Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.

Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. Li S, et al. Among authors: yu j. Cancer Res. 2019 May 15;79(10):2580-2592. doi: 10.1158/0008-5472.CAN-18-2812. Epub 2019 Apr 5. Cancer Res. 2019. PMID: 30952632 Free PMC article.

7

A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.

Rodríguez Y, Unno K, Truica MI, Chalmers ZR, Yoo YA, Vatapalli R, Sagar V, Yu J, Lysy B, Hussain M, Han H, Abdulkadir SA. Rodríguez Y, et al. Among authors: yu j. Cancer Res. 2022 Jun 6;82(11):2110-2123. doi: 10.1158/0008-5472.CAN-21-3565. Cancer Res. 2022. PMID: 35405009 Free PMC article.

8

Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.

Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner JM, Zynger DL, Eeckhoute J, Yu J, Luo J, Brown M, Clinton SK, Nephew KP, Huang TH, Li W, Wang Q. Zhang C, et al. Among authors: yu j. Cancer Res. 2011 Nov 1;71(21):6738-6748. doi: 10.1158/0008-5472.CAN-11-1882. Epub 2011 Sep 7. Cancer Res. 2011. PMID: 21900400 Free PMC article.

9

The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.

Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, Will C, Neri A, Kelleher NL, Yu J, Licht JD. Ezponda T, et al. Among authors: yu j. Oncogene. 2013 Jun 6;32(23):2882-90. doi: 10.1038/onc.2012.297. Epub 2012 Jul 16. Oncogene. 2013. PMID: 22797064 Free PMC article.

10

EZH2, an epigenetic driver of prostate cancer.

Yang YA, Yu J. Yang YA, et al. Among authors: yu j. Protein Cell. 2013 May;4(5):331-41. doi: 10.1007/s13238-013-2093-2. Epub 2013 Apr 30. Protein Cell. 2013. PMID: 23636686 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43,616 results

Search Page